Vetoquinol's (EPA:VETO) Shareholders Will Receive A Bigger Dividend Than Last Year

The board of Vetoquinol SA (EPA:VETO) has announced that it will be paying its dividend of €0.89 on the 6th of June, an increased payment from last year's comparable dividend. Although the dividend is now higher, the yield is only 1.2%, which is below the industry average.

Advertisement

Vetoquinol's Payment Could Potentially Have Solid Earnings Coverage

Even a low dividend yield can be attractive if it is sustained for years on end. However, prior to this announcement, Vetoquinol's dividend was comfortably covered by both cash flow and earnings. This means that most of what the business earns is being used to help it grow.

Over the next year, EPS is forecast to expand by 14.5%. If the dividend continues on this path, the payout ratio could be 17% by next year, which we think can be pretty sustainable going forward.

historic-dividend
ENXTPA:VETO Historic Dividend May 23rd 2025

View our latest analysis for Vetoquinol

Dividend Volatility

The company has a long dividend track record, but it doesn't look great with cuts in the past. Since 2015, the dividend has gone from €0.39 total annually to €0.89. This means that it has been growing its distributions at 8.6% per annum over that time. We have seen cuts in the past, so while the growth looks promising we would be a little bit cautious about its track record.

The Dividend Looks Likely To Grow

With a relatively unstable dividend, it's even more important to see if earnings per share is growing. We are encouraged to see that Vetoquinol has grown earnings per share at 16% per year over the past five years. A low payout ratio and decent growth suggests that the company is reinvesting well, and it also has plenty of room to increase the dividend over time.

Vetoquinol Looks Like A Great Dividend Stock

Overall, a dividend increase is always good, and we think that Vetoquinol is a strong income stock thanks to its track record and growing earnings. Distributions are quite easily covered by earnings, which are also being converted to cash flows. Taking this all into consideration, this looks like it could be a good dividend opportunity.

Market movements attest to how highly valued a consistent dividend policy is compared to one which is more unpredictable. Meanwhile, despite the importance of dividend payments, they are not the only factors our readers should know when assessing a company. Earnings growth generally bodes well for the future value of company dividend payments. See if the 6 Vetoquinol analysts we track are forecasting continued growth with our free report on analyst estimates for the company. Looking for more high-yielding dividend ideas? Try our collection of strong dividend payers.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About ENXTPA:VETO

Vetoquinol

A veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products for cattle, pigs, dogs, and cats in Europe, the Americas, and the Asia Pacific region.

Flawless balance sheet and good value.

Advertisement

Weekly Picks

LO
Lou_Basenese
GANX logo
Lou_Basenese on Gain Therapeutics ·

The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake

Fair Value:US$7.673.0% undervalued
27 users have followed this narrative
0 users have commented on this narrative
17 users have liked this narrative
KI
NVDA logo
Kingman1152 on NVIDIA ·

NVIDIA will see a profit margin surge of 55% in the next 5 years

Fair Value:US$305.233.9% undervalued
53 users have followed this narrative
1 users have commented on this narrative
19 users have liked this narrative
TE
BUSER logo
TechMegaTrends on Bambuser ·

Bambuser is today the only listed company in Europe that simultaneously possesses an 85% gross margin, proprietary AI infrastructure for the

Fair Value:SEK 238.2686.6% undervalued
33 users have followed this narrative
0 users have commented on this narrative
14 users have liked this narrative
HE
HedgeY
CSTM logo
HedgeY on Constellium ·

Constellium jet another cyclical aluminum processor, or a mispriced aluminum platform?

Fair Value:US$3413.0% undervalued
5 users have followed this narrative
0 users have commented on this narrative
4 users have liked this narrative

Updated Narratives

ST
StructuredAlpha
IREN logo
StructuredAlpha on IREN ·

IREN Thesis: From Miner to AI Infrastructure Leader

Fair Value:US$7031.3% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
HE
HedgeY
NEXA logo
HedgeY on Nexa Resources ·

Nexa; an integrated base-metals platform with real cash-flow torque?

Fair Value:US$156.7% overvalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
HE
HedgeY
EMBJ3 logo
HedgeY on Embraer ·

Simply a smaller aircraft manufacturer benefiting from an Aerospace Upcycle, or is it a niche aerospace platform with moat?

Fair Value:R$14040.7% undervalued
2 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

TR
tripledub
MSFT logo
tripledub on Microsoft ·

Everyone's Terrified Microsoft Will Keep Spending. I'm Terrified They'll Stop.

Fair Value:US$3957.0% overvalued
51 users have followed this narrative
3 users have commented on this narrative
43 users have liked this narrative
KI
NVDA logo
Kingman1152 on NVIDIA ·

NVIDIA will see a profit margin surge of 55% in the next 5 years

Fair Value:US$305.233.9% undervalued
53 users have followed this narrative
1 users have commented on this narrative
19 users have liked this narrative
AN
AnalystConsensusTarget
MSFT logo
AnalystConsensusTarget on Microsoft ·

Analyst Commentary Highlights Microsoft AI Momentum and Upward Valuation Amid Growth and Competitive Risks

Fair Value:US$587.3128.0% undervalued
1365 users have followed this narrative
2 users have commented on this narrative
11 users have liked this narrative

Trending Discussion

SP
EOSE logo
spearfishingcap on Eos Energy Enterprises ·

AI Slop

1
|
0
MA
BBW logo
manunogueira on Build-A-Bear Workshop ·

Why so high p/e?

0
|
0